Core Viewpoint - Shengmei Shanghai (688082.SH) reported a total order backlog of 9.072 billion yuan as of September 29, 2025, representing a year-on-year increase of 34.10% compared to the voluntarily disclosed order data from the same period last year [1] Summary by Category - **Company Performance** - The total order backlog reached 9.072 billion yuan [1] - There is a significant year-on-year growth of 34.10% in the order backlog [1]

Group 1 - Yinglian Co., Ltd. expects a net profit of 34.5 million to 37.5 million yuan for the first three quarters of 2025, representing a year-on-year increase of 1531% to 1673% [1] - China CNR Corporation signed major contracts totaling approximately 54.34 billion yuan, accounting for 22% of its expected revenue for 2024 [1] - Shengmei Shanghai reported a total order amount of 9.072 billion yuan, a year-on-year increase of 34.1% [2] Group 2 - Fulian Precision plans to increase capital in its subsidiary Jiangxi Shenghua with a total investment of 35.63 billion yuan, which is expected to constitute a major asset restructuring [3] - Aimeike has obtained a drug registration certificate for Minoxidil topical solution, which is used for treating male pattern baldness [4] - Guolin Technology is planning to acquire 91.07% of Kailianjie’s equity for cash, which is expected to constitute a major asset restructuring [5] Group 3 - Baicheng Co. plans to purchase 55% of Shanghai Canxi Engineering Equipment Co. and will suspend trading of its stock starting September 30, 2025 [6][7] - Diaowei is planning to acquire equity in Rongpai Semiconductor and has suspended trading of its stock [8] - Xiatun New Energy signed a strategic cooperation framework agreement with Zhongwei Co. to establish a long-term partnership in the supply chain for solid-state lithium battery materials [9] Group 4 - Lingyi Zhi Manufacturing is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international strategy [10] - Baicheng Pharmaceutical received clinical trial approval for its innovative drug BIOS-0623-Z4, which targets cancer pain treatment [11] - Weide Information announced a preliminary transfer price of 40.33 yuan per share, representing a 26% discount to its closing price [12] Group 5 - Huayou Cobalt's subsidiary signed contracts with LGES for the supply of 76,000 tons of ternary precursor materials and 88,000 tons of ternary cathode materials from 2026 to 2030 [13] - Hubei Energy signed a cooperation agreement with the Xiangyang Municipal Government to invest 26.7 billion yuan in clean energy projects [14]

每经头条（nbdtoutiao）——农夫大战怡宝，抢到更多蛋糕的却是宗馥莉！农夫绿瓶上市后，怡宝上 演"滑铁卢"：市占率大跌近5个百分点 （记者 曾健辉） 每经AI快讯，盛美上海（SH 688082，收盘价：202.88元）9月29日晚间发布公告称，本次发行完成后， 公司新增股份数约3860万股，发行价格116.11元/股，募集资金总额约44.82亿元。发行对象认购的股份 自发行结束之日起六个月内不得转让。 截至发稿，盛美上海市值为895亿元。 ...

Core Viewpoint - Since 2025, the demand for semiconductor equipment in China has remained strong, leading to steady revenue growth for the company due to its technological advantages, product maturity, and market recognition [1] Company Summary - As of September 29, 2025, the company's total order backlog amounts to 9.072 billion yuan, representing a year-on-year increase of 34.10% compared to the voluntarily disclosed order data from the previous year [1]

盛美半导体设备（上海）股份有限公司 （中国（上海）自由贸易试验区丹桂路 999 弄 5、6、7、8 号全幢） 2024 年度向特定对象发行 A 股股票 上市公告书 股票代码：688082 股票简称：盛美上海 中国（上海）自由贸易试验区商城路 618 号 保荐人（主承销商） 联席主承销商 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 深圳市前海深港合作区南山街道桂湾五路 128 号前海深港基金小镇 B7 栋 401 二〇二五年九月 特别提示 一、发行数量及价格 3、募集资金总额：人民币 4,481,999,961.86 元 4、募集资金净额：人民币 4,435,015,697.05 元 二、本次发行股票预计上市时间 本次发行新增股份将于限售期届满后的次一交易日起在上海证券交易所上 市流通交易，如遇法定节假日或休息日，则顺延至其后的第一个交易日。 三、新增股份的限售安排 本次发行对象共有 17 名，均以现金方式参与认购，全部发行对象认购的股 票自发行结束之日起六个月内不得转让。法律法规、规范性文件对限售期另有 规定的，依其规定。发行对象基于本次交易所取得的公司向特定对象发行的股 票，因公司分配股票股 ...

关于盛美半导体设备（上海）股份有限公司 2024 年度向特定对象发行 A 股股票 之 上市保荐书 国泰海通证券股份有限公司 保荐人（主承销商） | 一、发行人基本情况 3 | | --- | | 二、发行人本次发行情况 15 | | 三、本次证券发行上市的项目保荐代表人、协办人及项目组其他成员情况 17 | | 四、保荐机构是否存在可能影响公正履行保荐职责情形的说明 18 | | 五、保荐机构承诺事项 18 | | 六、本次证券发行上市履行的决策程序 20 | | 七、保荐机构关于符合国家产业政策和板块定位的核查情况 22 | | 八、本次向特定对象发行股票符合规定 23 | | 九、保荐机构对发行人持续督导工作的安排 27 | | 十、保荐机构和保荐代表人联系方式 28 | | 十一、保荐机构认为应当说明的其他事项 28 | | 十二、保荐机构对本次股票上市的推荐结论 28 | 一、发行人基本情况 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"或"保 荐人"）及其保荐代表人已根据《中华人民共和国公司法》（以下简称《公司法》）、 《中华人民共和国证券法》（以下简称《证券法》）、《上市公司证券发行 ...

证券代码：688082 证券简称：盛美上海 公告编号：2025-068 盛美半导体设备（上海）股份有限公司 关于 2024 年度向特定对象发行 A 股股票 发行结果暨股本变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 预计上市时间：盛美半导体设备（上海）股份有限公司（以下简称"公 司"、"盛美上海"或"发行人"）本次发行新增股份38,601,326股已于2025年9 月26日在中国证券登记结算有限责任公司上海分公司办理完毕股份登记手续。本 次发行新增股份为有限售条件流通股，将于限售期届满后的次一交易日起在上海 证券交易所上市流通交易，如遇法定节假日或休息日，则顺延至其后的第一个交 易日。 本次发行完成后，发行对象认购的股份自发行结束之日起六个月内不得转让。 法律法规、规范性文件对限售期另有规定的，依其规定。发行对象基于本次交易 所取得的公司向特定对象发行的股票，因公司分配股票股利、资本公积转增股本 等情形所衍生取得的股份亦应遵守上述股份锁定安排。发行对象因本次交易取得 的公司股份在限售期届满后减持 ...

证券代码：688082 证券简称：盛美上海 公告编号：2025-069 盛美半导体设备（上海）股份有限公司 关于在手订单情况的自愿性披露公告 3、以上在手订单数据源自公司内部统计，未经审计，不能以此直接推算公 司全年营业收入、净利润等财务数据，仅供投资者及时了解公司日常经营概况。 具体准确的财务数据以公司正式披露的定期报告为准，敬请广大投资者注意投资 风险。 特此公告。 盛美半导体设备（上海）股份有限公司（以下简称"公司"）从事对集成电 路制造与先进晶圆级封装制造行业至关重要的单晶圆及槽式湿法清洗设备、电镀 设备、无应力抛光设备、立式炉管设备、前道涂胶显影设备和等离子体增强化学 气相沉积设备等的研发、制造和销售。2025年以来，中国半导体行业设备需求持 续旺盛，公司凭借技术优势、产品成熟度和市场认可度，不断深耕现有市场、拓 展新市场，收入稳步增长。为让投资者更好地了解公司经营情况，现将截至2025 年9月29日的在手合同订单情况公告如下： 一、截至2025年9月29日在手订单情况 截至2025年9月29日，公司在手订单总金额为907,153.57万元，与上年同期 已自愿性披露的在手订单数据相比，在手订单总金额 ...

Core Viewpoint - Shengmei Shanghai (688082.SH) reported a total order backlog of 9.072 billion yuan as of September 29, 2025, representing a year-on-year increase of 34.10% [1] Group 1 - The total order backlog includes equipment orders that have been delivered to customers but not yet recognized as revenue, as well as equipment orders that will be delivered in the future [1]

Core Insights - The company announced that as of September 29, 2025, its total backlog of orders amounts to 9.072 billion yuan, representing a 34.10% increase compared to the same period last year [1] Summary by Categories Order Backlog - The total backlog includes equipment orders that have been delivered to customers but have not yet received customer confirmation of revenue, as well as equipment orders that will be delivered in the future [1] - The backlog data is sourced from the company's internal statistics and is unaudited, intended to provide investors with timely insights into the company's operational status [1] Financial Impact - The backlog is subject to specific execution and implementation progress, which introduces uncertainty regarding its impact on the company's current and future financial performance [1] - Accurate financial data will be disclosed in the company's formal periodic reports [1]